Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Vyvanse CII Significantly Improved ADHD Symptoms For Children 13 Hours After Administration
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, has announced that a study published online in the peer-reviewed journal Child and Adolescent Psychiatry and Mental Health found once-daily Vyvanse® (lisdexamfetamine dimesylate) CII significantly reduced the symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6 to 12 from the first time point measured (1.5 hours) up to the last time point assessed (13 hours) after administration. In this pediatric analog classroom study, treatment with Vyvanse was associated with significant improvement in behavior and attention in children at each time point measured, with improvement at 13 hours after administration.

CEL-SCI Developing Immune-Based Treatment Against Swine And Other H1N1 Flu Viruses Using Proprietary L.E.A.P.S. Technology
CEL-SCI Corporation (NYSE AMEX: CVM) announced that it is developing an immune-based treatment for the "swine flu and related H1N1" flu viruses, utilizing its proprietary L.E.A.P.S.(TM) (Ligand Epitope Antigen Presentation System) vaccine technology. The Company plans to utilize the expertise and knowledge it has gained from developing protective and therapeutic vaccines utilizing L.E.A.P.S. to develop a therapeutic treatment based upon the technology for people infected with the swine and H1N1 flu viruses. CEL-SCI has already commenced pre-clinical testing.
News of the day
Connecticut House Approves Two Health Insurance Pooling Bills
The Connecticut House on Wednesday approved two separate measures to expand health insurance pooling in the state, the Hartford Courant reports. The first measure would create a public health insurance pool open to all residents. The pool, intended to compete with rather than replace private insurance, would be based on the existing pool for state workers (Keating, Hartford Courant, 5/21). The bill will create a nine-member board of directors to investigate and recommend a plan to guarantee every resident health insurance. The bill also creates four committees that will work with the board and provide advice on electronic health records, medical homes, clinical care guidelines and preventive care. In addition, three task forces will examine obesity, tobacco use and care provider shortages (Stuart, CT News Junkie, 5/20).The cost of plan, known as SustiNet, could be a "sticking point" given the state"s $8.7 billion budget deficit over the next two years, the Courant reports The state Senate and Gov. Jodi Rell (R) will consider the plan next.The second measure would allow local governments, small businesses and not-for-profit groups join the state employee insurance plan. The bill would increase the current pool"s membership from 200,000 to an estimated 300,000. Juan Figueroa, a former state legislator and president of the Universal Health Care Foundation of Connecticut, said, "Both of these plans reduce costs and increase choice. The partnership (pooling) bill has features that SustiNet can build on. The two bills fit hand in glove." Democrats said the second bill would utilize economies of scale to lower costs. Steve Fontana (D), co-chair of the State House Insurance and Real Estate Committee, said, "The larger the pool you have, ... you reduce the volatility and the risk associated with that pool."Opponents say the pooling measure would affect only those who already have coverage. According to House Republican Leader Larry Cafero, "This bill does not solve that problem. If you don"t have it now, you"re not going to have it because of this" (Keating, Hartford Courant, 5/21).
Mental Health

Psychotherapy Of Depression Changes Biological Parameters?

A group of German investigators demonstrated that the early increase in phosphorylated CREB (pCREB) is related to treatment response and does not depend on pharmacological interventions or brain-derived neurotrophic factor (BDNF) plasma levels. For the first time, cellular biological markers could be associated with response to psychotherapy. The cyclic adenosine monophosphate response element-binding proteins (CREB) and their interaction with brain-derived neurotrophic factor (BDNF) are essential elements in signal transduction pathways important for cellular resilience and neuroplasticity. They play a decisive role in the concept of altered neuroplasticity in major depression. The Authors of this study have previously demonstrated that the increase in phosphorylated CREB (pCREB) in T lymphocytes is significantly associated with clinical improvement in patients treated with antidepressants. In the present study, they focused on patients treated only with psychotherapy to exclude direct pharmacological actions. In addition to pCREB, they also measured the BDNF plasma levels. pCREB in T lymphocytes was determined by Western blot; the BDNF plasma levels with solid-phase ELISA. Psychopathology was evaluated with the Hamilton Rating Scale for Depression (HAMD). Thirty patients meeting DSM-IV criteria for major depressive episodes (MDE) were recruited into this 6-week study. They received interpersonal psychotherapy (IPT) twice weekly. After 6 weeks of IPT, 17 patients responded (reduction of 50% of baseline HAMD); after 1 week of treatment pCREB increased significantly compared to the nonresponder group. Measurement of the BDNF plasma levels revealed no differences between the responder and nonresponder groups. Furthermore, the correlations between BDNF plasma levels and pCREB were not significant. The early increase in pCREB is related to treatment response and does not depend on pharmacological interventions or BDNF plasma levels. For the first time, cellular biological markers could be associated with response to psychotherapy. Psychotherapy and Psychosomatics


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009